Nat Med:癌症耐药新机制

2018-02-14 Ruthy,Yui 转化医学网

基底细胞癌(BCC)是最为常见的皮肤癌类型,基于它有较大的破坏性,又称侵袭性溃疡。这是一种严重破坏容貌的癌症,但较少危及生命。最新的一项研究表明,BCC肿瘤细胞中存在着一种 不依赖于基因突变的药物抵抗机制,使得许多的皮肤癌患者在诊断时即存在着耐药性。这项研究成果有利于对BCC患者进行更有效的治疗并为个人专项治疗提供理论基础。

基底细胞癌(BCC)是最为常见的皮肤癌类型,基于它有较大的破坏性,又称侵袭性溃疡。这是一种严重破坏容貌的癌症,但较少危及生命。最新的一项研究表明,BCC肿瘤细胞中存在着一种 不依赖于基因突变的药物抵抗机制,使得许多的皮肤癌患者在诊断时即存在着耐药性。这项研究成果有利于对BCC患者进行更有效的治疗并为个人专项治疗提供理论基础。

斯坦福大学的研究人员发现BCC癌细胞内部骨架的变化与驱动细胞生长的信号传导途径间存在着一定联系,这一发现使得癌细胞在未发生基因突变的情况下也能避开药物的作用。

研究人员通过进一步的研究,他们发现了BCC抗药机制的控制因子,而这些因子有望成为BCC新疗法的靶点。该研究成果以《Noncanonical hedgehog pathway activation through SRF–MKL1 promotes drug resistance in basal cell carcinomas》为题发表在2月5日的《Nature Medicine》上。

研究结果表明,BCC癌细胞能将蛋白质导入细胞核来提高分子级联反应-Hedgehog途径的活性,从而避开药物治疗。Hedgehog信号途径可将信号从细胞外传递至细胞核,触发细胞生长发育相关基因的表达。

该途径对于人类发育至关重要,并在许多类型的癌症(胰腺癌结肠癌肺癌乳腺癌和髓母细胞等)中都起作用。

Hedgehog是一种共价结合胆固醇的分泌性蛋白,两个跨膜蛋白Patched(Ptc)和Smoothened(Smo)介导Hedgehog信号向胞内传递。Hedgehog信号途径的转录因子是GLI1,Ptc和Smo、GLI1的表达和信号传递存在负反馈调节。BCC普遍存在Ptc或Smo突变,打破了Hedgehog信号途径的负反馈调节网络,导致GLI1异常激活,癌细胞快速大量生长,药物的疗效赶不上肿瘤细胞的生长速度,自然是“耐药”了。


人肿瘤特征的 BCC耐药小鼠模型的产生

文章的第一作者Whitson博士发现Hedgehog通路的SRF转录因子和GLI11蛋白能在发生抗药性的癌症中保持活性。同时SRF可由MKL1蛋白激活。MKL1蛋白与细胞骨架成分的合成有关,可保持细胞形状并控制细胞刚性。由于SRF和MKL1皆于Hedgehog途径的最后一步中存在,因此即在信号级联的早期进行阻断,它们也能刺激癌细胞的生长。


基因组分析确定SRF为BCC中Hedgehog途径异常活化的辅因子


研究结果表明SRF和MKL1是BCC生长和hedgehog通路活性增强所必需的

研究人员发现耐药癌细胞中的核MKL1蛋白水平明显高于正常细胞,他们阻断了MKL1合成,同时增加GLI1活性,最终显着减缓实验鼠BCC癌细胞的生长。此外,在实验室中生长的人类原发性BCC细胞也对该操作作出了反应,突出了这种方法的治疗潜力。


MKL1的药理学抑制在小鼠和人BCC中产生治疗应答

该研究成果表明这种方法可能有利于BCC患者的治疗,同时能帮助研究人员制定更好的个性化治疗方案。此外,研究人员还可以将核MKL1作为生物标志物,用以辨别可能从MKL1或GLI1抑制剂治疗中大幅获益的患者。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1882854, encodeId=30eb188285401, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 11 14:53:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756218, encodeId=d0a81e56218dd, content=<a href='/topic/show?id=ddf2e146989' target=_blank style='color:#2F92EE;'>#癌症耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71469, encryptionId=ddf2e146989, topicName=癌症耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09c937078197, createdName=spoonycyy, createdTime=Wed Sep 26 03:53:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293062, encodeId=f2052930624e, content=不错.希望对各种肿瘤有帮助, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erK1WhXxUtQFV7kmIyCaHlvuo3ABySzfwe1sPsXPYicXto30vXQ5ukZtKgpU9IkZ9HRRDzMMfYqwVQ/132, createdBy=19a82282835, createdName=guibaoliu, createdTime=Mon Mar 05 01:16:33 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608571, encodeId=e89716085e181, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 16 02:53:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288241, encodeId=977928824193, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Thu Feb 15 22:26:10 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288082, encodeId=f56c2880826d, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Thu Feb 15 07:26:39 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288078, encodeId=52f32880e852, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Feb 15 07:24:16 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287899, encodeId=151728e8993e, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Wed Feb 14 12:15:14 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287895, encodeId=12ad28e895e7, content=这种方法可能有利于BCC患者的治疗.同时能帮助研究人员制定更好的个性化治疗方案, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUlbw1Mf1vppicGcaWPx1YUOgLgKccao77Rykbx3jiazqzwcyXMdzRIZkhFyBPqknibeuOGhXI1VzVg/0, createdBy=7f162154630, createdName=沙漠浪人, createdTime=Wed Feb 14 12:04:30 CST 2018, time=2018-02-14, status=1, ipAttribution=)]
    2018-05-11 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1882854, encodeId=30eb188285401, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 11 14:53:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756218, encodeId=d0a81e56218dd, content=<a href='/topic/show?id=ddf2e146989' target=_blank style='color:#2F92EE;'>#癌症耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71469, encryptionId=ddf2e146989, topicName=癌症耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09c937078197, createdName=spoonycyy, createdTime=Wed Sep 26 03:53:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293062, encodeId=f2052930624e, content=不错.希望对各种肿瘤有帮助, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erK1WhXxUtQFV7kmIyCaHlvuo3ABySzfwe1sPsXPYicXto30vXQ5ukZtKgpU9IkZ9HRRDzMMfYqwVQ/132, createdBy=19a82282835, createdName=guibaoliu, createdTime=Mon Mar 05 01:16:33 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608571, encodeId=e89716085e181, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 16 02:53:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288241, encodeId=977928824193, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Thu Feb 15 22:26:10 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288082, encodeId=f56c2880826d, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Thu Feb 15 07:26:39 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288078, encodeId=52f32880e852, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Feb 15 07:24:16 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287899, encodeId=151728e8993e, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Wed Feb 14 12:15:14 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287895, encodeId=12ad28e895e7, content=这种方法可能有利于BCC患者的治疗.同时能帮助研究人员制定更好的个性化治疗方案, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUlbw1Mf1vppicGcaWPx1YUOgLgKccao77Rykbx3jiazqzwcyXMdzRIZkhFyBPqknibeuOGhXI1VzVg/0, createdBy=7f162154630, createdName=沙漠浪人, createdTime=Wed Feb 14 12:04:30 CST 2018, time=2018-02-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1882854, encodeId=30eb188285401, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 11 14:53:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756218, encodeId=d0a81e56218dd, content=<a href='/topic/show?id=ddf2e146989' target=_blank style='color:#2F92EE;'>#癌症耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71469, encryptionId=ddf2e146989, topicName=癌症耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09c937078197, createdName=spoonycyy, createdTime=Wed Sep 26 03:53:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293062, encodeId=f2052930624e, content=不错.希望对各种肿瘤有帮助, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erK1WhXxUtQFV7kmIyCaHlvuo3ABySzfwe1sPsXPYicXto30vXQ5ukZtKgpU9IkZ9HRRDzMMfYqwVQ/132, createdBy=19a82282835, createdName=guibaoliu, createdTime=Mon Mar 05 01:16:33 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608571, encodeId=e89716085e181, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 16 02:53:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288241, encodeId=977928824193, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Thu Feb 15 22:26:10 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288082, encodeId=f56c2880826d, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Thu Feb 15 07:26:39 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288078, encodeId=52f32880e852, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Feb 15 07:24:16 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287899, encodeId=151728e8993e, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Wed Feb 14 12:15:14 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287895, encodeId=12ad28e895e7, content=这种方法可能有利于BCC患者的治疗.同时能帮助研究人员制定更好的个性化治疗方案, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUlbw1Mf1vppicGcaWPx1YUOgLgKccao77Rykbx3jiazqzwcyXMdzRIZkhFyBPqknibeuOGhXI1VzVg/0, createdBy=7f162154630, createdName=沙漠浪人, createdTime=Wed Feb 14 12:04:30 CST 2018, time=2018-02-14, status=1, ipAttribution=)]
    2018-03-05 guibaoliu

    不错.希望对各种肿瘤有帮助

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1882854, encodeId=30eb188285401, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 11 14:53:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756218, encodeId=d0a81e56218dd, content=<a href='/topic/show?id=ddf2e146989' target=_blank style='color:#2F92EE;'>#癌症耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71469, encryptionId=ddf2e146989, topicName=癌症耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09c937078197, createdName=spoonycyy, createdTime=Wed Sep 26 03:53:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293062, encodeId=f2052930624e, content=不错.希望对各种肿瘤有帮助, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erK1WhXxUtQFV7kmIyCaHlvuo3ABySzfwe1sPsXPYicXto30vXQ5ukZtKgpU9IkZ9HRRDzMMfYqwVQ/132, createdBy=19a82282835, createdName=guibaoliu, createdTime=Mon Mar 05 01:16:33 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608571, encodeId=e89716085e181, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 16 02:53:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288241, encodeId=977928824193, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Thu Feb 15 22:26:10 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288082, encodeId=f56c2880826d, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Thu Feb 15 07:26:39 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288078, encodeId=52f32880e852, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Feb 15 07:24:16 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287899, encodeId=151728e8993e, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Wed Feb 14 12:15:14 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287895, encodeId=12ad28e895e7, content=这种方法可能有利于BCC患者的治疗.同时能帮助研究人员制定更好的个性化治疗方案, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUlbw1Mf1vppicGcaWPx1YUOgLgKccao77Rykbx3jiazqzwcyXMdzRIZkhFyBPqknibeuOGhXI1VzVg/0, createdBy=7f162154630, createdName=沙漠浪人, createdTime=Wed Feb 14 12:04:30 CST 2018, time=2018-02-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1882854, encodeId=30eb188285401, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 11 14:53:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756218, encodeId=d0a81e56218dd, content=<a href='/topic/show?id=ddf2e146989' target=_blank style='color:#2F92EE;'>#癌症耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71469, encryptionId=ddf2e146989, topicName=癌症耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09c937078197, createdName=spoonycyy, createdTime=Wed Sep 26 03:53:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293062, encodeId=f2052930624e, content=不错.希望对各种肿瘤有帮助, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erK1WhXxUtQFV7kmIyCaHlvuo3ABySzfwe1sPsXPYicXto30vXQ5ukZtKgpU9IkZ9HRRDzMMfYqwVQ/132, createdBy=19a82282835, createdName=guibaoliu, createdTime=Mon Mar 05 01:16:33 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608571, encodeId=e89716085e181, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 16 02:53:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288241, encodeId=977928824193, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Thu Feb 15 22:26:10 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288082, encodeId=f56c2880826d, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Thu Feb 15 07:26:39 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288078, encodeId=52f32880e852, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Feb 15 07:24:16 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287899, encodeId=151728e8993e, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Wed Feb 14 12:15:14 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287895, encodeId=12ad28e895e7, content=这种方法可能有利于BCC患者的治疗.同时能帮助研究人员制定更好的个性化治疗方案, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUlbw1Mf1vppicGcaWPx1YUOgLgKccao77Rykbx3jiazqzwcyXMdzRIZkhFyBPqknibeuOGhXI1VzVg/0, createdBy=7f162154630, createdName=沙漠浪人, createdTime=Wed Feb 14 12:04:30 CST 2018, time=2018-02-14, status=1, ipAttribution=)]
    2018-02-15 changjiu

    学习一下谢谢

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1882854, encodeId=30eb188285401, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 11 14:53:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756218, encodeId=d0a81e56218dd, content=<a href='/topic/show?id=ddf2e146989' target=_blank style='color:#2F92EE;'>#癌症耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71469, encryptionId=ddf2e146989, topicName=癌症耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09c937078197, createdName=spoonycyy, createdTime=Wed Sep 26 03:53:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293062, encodeId=f2052930624e, content=不错.希望对各种肿瘤有帮助, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erK1WhXxUtQFV7kmIyCaHlvuo3ABySzfwe1sPsXPYicXto30vXQ5ukZtKgpU9IkZ9HRRDzMMfYqwVQ/132, createdBy=19a82282835, createdName=guibaoliu, createdTime=Mon Mar 05 01:16:33 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608571, encodeId=e89716085e181, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 16 02:53:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288241, encodeId=977928824193, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Thu Feb 15 22:26:10 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288082, encodeId=f56c2880826d, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Thu Feb 15 07:26:39 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288078, encodeId=52f32880e852, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Feb 15 07:24:16 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287899, encodeId=151728e8993e, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Wed Feb 14 12:15:14 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287895, encodeId=12ad28e895e7, content=这种方法可能有利于BCC患者的治疗.同时能帮助研究人员制定更好的个性化治疗方案, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUlbw1Mf1vppicGcaWPx1YUOgLgKccao77Rykbx3jiazqzwcyXMdzRIZkhFyBPqknibeuOGhXI1VzVg/0, createdBy=7f162154630, createdName=沙漠浪人, createdTime=Wed Feb 14 12:04:30 CST 2018, time=2018-02-14, status=1, ipAttribution=)]
    2018-02-15 神功盖世

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1882854, encodeId=30eb188285401, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 11 14:53:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756218, encodeId=d0a81e56218dd, content=<a href='/topic/show?id=ddf2e146989' target=_blank style='color:#2F92EE;'>#癌症耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71469, encryptionId=ddf2e146989, topicName=癌症耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09c937078197, createdName=spoonycyy, createdTime=Wed Sep 26 03:53:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293062, encodeId=f2052930624e, content=不错.希望对各种肿瘤有帮助, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erK1WhXxUtQFV7kmIyCaHlvuo3ABySzfwe1sPsXPYicXto30vXQ5ukZtKgpU9IkZ9HRRDzMMfYqwVQ/132, createdBy=19a82282835, createdName=guibaoliu, createdTime=Mon Mar 05 01:16:33 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608571, encodeId=e89716085e181, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 16 02:53:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288241, encodeId=977928824193, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Thu Feb 15 22:26:10 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288082, encodeId=f56c2880826d, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Thu Feb 15 07:26:39 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288078, encodeId=52f32880e852, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Feb 15 07:24:16 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287899, encodeId=151728e8993e, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Wed Feb 14 12:15:14 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287895, encodeId=12ad28e895e7, content=这种方法可能有利于BCC患者的治疗.同时能帮助研究人员制定更好的个性化治疗方案, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUlbw1Mf1vppicGcaWPx1YUOgLgKccao77Rykbx3jiazqzwcyXMdzRIZkhFyBPqknibeuOGhXI1VzVg/0, createdBy=7f162154630, createdName=沙漠浪人, createdTime=Wed Feb 14 12:04:30 CST 2018, time=2018-02-14, status=1, ipAttribution=)]
    2018-02-15 sunfeifeiyang

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1882854, encodeId=30eb188285401, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 11 14:53:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756218, encodeId=d0a81e56218dd, content=<a href='/topic/show?id=ddf2e146989' target=_blank style='color:#2F92EE;'>#癌症耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71469, encryptionId=ddf2e146989, topicName=癌症耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09c937078197, createdName=spoonycyy, createdTime=Wed Sep 26 03:53:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293062, encodeId=f2052930624e, content=不错.希望对各种肿瘤有帮助, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erK1WhXxUtQFV7kmIyCaHlvuo3ABySzfwe1sPsXPYicXto30vXQ5ukZtKgpU9IkZ9HRRDzMMfYqwVQ/132, createdBy=19a82282835, createdName=guibaoliu, createdTime=Mon Mar 05 01:16:33 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608571, encodeId=e89716085e181, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 16 02:53:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288241, encodeId=977928824193, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Thu Feb 15 22:26:10 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288082, encodeId=f56c2880826d, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Thu Feb 15 07:26:39 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288078, encodeId=52f32880e852, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Feb 15 07:24:16 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287899, encodeId=151728e8993e, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Wed Feb 14 12:15:14 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287895, encodeId=12ad28e895e7, content=这种方法可能有利于BCC患者的治疗.同时能帮助研究人员制定更好的个性化治疗方案, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUlbw1Mf1vppicGcaWPx1YUOgLgKccao77Rykbx3jiazqzwcyXMdzRIZkhFyBPqknibeuOGhXI1VzVg/0, createdBy=7f162154630, createdName=沙漠浪人, createdTime=Wed Feb 14 12:04:30 CST 2018, time=2018-02-14, status=1, ipAttribution=)]
    2018-02-14 神功盖世

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1882854, encodeId=30eb188285401, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 11 14:53:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756218, encodeId=d0a81e56218dd, content=<a href='/topic/show?id=ddf2e146989' target=_blank style='color:#2F92EE;'>#癌症耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71469, encryptionId=ddf2e146989, topicName=癌症耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09c937078197, createdName=spoonycyy, createdTime=Wed Sep 26 03:53:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293062, encodeId=f2052930624e, content=不错.希望对各种肿瘤有帮助, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erK1WhXxUtQFV7kmIyCaHlvuo3ABySzfwe1sPsXPYicXto30vXQ5ukZtKgpU9IkZ9HRRDzMMfYqwVQ/132, createdBy=19a82282835, createdName=guibaoliu, createdTime=Mon Mar 05 01:16:33 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608571, encodeId=e89716085e181, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 16 02:53:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288241, encodeId=977928824193, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Thu Feb 15 22:26:10 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288082, encodeId=f56c2880826d, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Thu Feb 15 07:26:39 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288078, encodeId=52f32880e852, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Feb 15 07:24:16 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287899, encodeId=151728e8993e, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Wed Feb 14 12:15:14 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287895, encodeId=12ad28e895e7, content=这种方法可能有利于BCC患者的治疗.同时能帮助研究人员制定更好的个性化治疗方案, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJUlbw1Mf1vppicGcaWPx1YUOgLgKccao77Rykbx3jiazqzwcyXMdzRIZkhFyBPqknibeuOGhXI1VzVg/0, createdBy=7f162154630, createdName=沙漠浪人, createdTime=Wed Feb 14 12:04:30 CST 2018, time=2018-02-14, status=1, ipAttribution=)]
    2018-02-14 沙漠浪人

    这种方法可能有利于BCC患者的治疗.同时能帮助研究人员制定更好的个性化治疗方案

    0

相关资讯

BMJ:TNF抑制剂可能降低类风湿性关节炎患者的鳞状细胞癌和基底细胞癌风险

该研究的目的是探讨未经生物药物治疗的类风湿性关节炎患者,开始使用肿瘤坏死因子(TNF)抑制剂治疗的患者,以及普通人群患鳞状细胞和基底细胞皮肤癌的风险。原始出处:Pauline Raaschou,Julia F Simard,Charlotte Asker Hagelberg,et al.Rheumatoid arthritis, anti-tumour necrosis factor treatm

BMJ:带蒂鼻结节-案例报道

该患者选择接受莫氏手术,并在随后进行鼻翼重建,随访三个月后,患者美容效果较好,没有复发的证据。

Br J Dermatol:局部光动力疗法治疗浅表性基底细胞癌时,是否应该采取二步光照法?

基底细胞癌(Basal cell carcinoma,BCC)是最常见的皮肤癌类型,其发病率明显呈上升趋势。光动力疗法(PDT)是一种常用的治疗BCC的方法,尤其针对浅表性BCC(SBCC)。目前有两种表面光敏化剂用于治疗SBCC:5-氨基乙酰丙酸(ALA)及其甲酯(MAL)。以往的研究表明,使用二步法光照的ALA-PDT疗法有更好的疗效,二步法光照指在应用ALA后的4小时和6小时时,分别的光照剂

NEJM:口服烟酰胺(VB3)可降低皮肤癌风险

非黑色素瘤皮肤癌如基底细胞癌、鳞状细胞癌,通常是由紫外线(UV)辐射导致的。而有研究表明烟酰胺(VB3)可以对UV造成的损伤产生拮抗保护作用,并且减少新的光化性角化病(癌前病变)。 研究者进行了一项双盲、随机、对照的3期试验,研究对象需满足以下条件:纳入研究前5年至少2种非黑色素瘤皮肤癌。研究者按1:1比例将386名研究对象分为2组,一组服用烟酰胺500mg ,每日两次;另一组则服用安慰剂,服药时

JCO:绝经后使用激素治疗导致基底细胞癌风险增加

基底细胞癌(BCC)作为人类最常见的恶性肿瘤,紫外线照射是其首要病因之一。过去几年的研究证实雌激素具有光敏化特征,但是关于生殖因素或外源性雌激素使用与BCC的研究却没有。因此研究者进行了一项大型的、国际的、前瞻性队列研究,评估生殖因素、外源性雌激素使用和原发BCC首次发生的风险间关系。研究结果发现,绝经年龄较晚的人群BCC风险更高 :≥55岁 vs 50-54岁 HR=1.50; 95% CI,

J Am Acad Dermatol:Vismodegib治疗皮肤基底细胞癌,并不会增加鳞状细胞癌风险

Vismodegib是治疗局部晚期基底细胞癌(basal cell carcinoma,BCC)和转移性BCC的一种靶向Hedgehog信号通路的首创新药。但在使用这种药物治疗的患者中继发性的鳞状细胞癌的风险还未确定。因此,来自美国的研究人员设计并完成了该研究,旨在确定vismodegib治疗是否与皮肤鳞状细胞癌的风险增加有关,他们将研究结果发表在了最新一期的上。